Digest Network Come funziona
Network
/
Società
Af
Non verificato

Affinia Therapeutics

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

6 comunicati stampa

Guarda tutti i comunicati
14/10/2025
Associazioni/Professionisti
Salute
Biotecnologia
Sanità
Finanza
Farmaceutica
Cardiologia
Eventi
Affinia Therapeutics to Participate in Upcoming Investor Conferences
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
07/10/2025
Salute
Tecnica
Biotecnologia
Medicina - Varie
Cardiologia
Affinia Therapeutics Announces Series C Financing to Advance New Class of Gene Therapies Intended to Provide Improved Safety and Efficacy
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
03/06/2025
Scienza
Biotecnologia
Cardiologia
Associazioni/Professionisti
Farmaceutica
Salute
Mercato del lavoro
Affinia Therapeutics and DCM Foundation Announce Partnership to Increase Awareness About BAG3 Dilated Cardiomyopathy and Critical Need for Genetic Testing to Help Save Lives
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
13/05/2025
Eventi
Industria
Cardiologia
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Affinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th American Society of Gene & Cell Therapy 2025 Annual Meeting
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Industria
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Affinia Therapeutics to Present New Data on its AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th Annual American Society of Gene & Cell Therapy 2025 Annual Meeting
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0
28/04/2025
Industria
Scienza
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Affinia Therapeutics to Present New Data on its AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th Annual American Society of Gene & Cell Therapy 2025 Annual Meeting
Fonte
Affinia Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0